HALIX, a corporate venture and spin-off of HAL Allergy, is a contract development and manufacturing organization (CDMO), based in Leiden (The Netherlands). The company is licensed for the contract manufacturing of clinical and commercial medicines according to GMP standards. HALIX leverages advanced biopharmaceutical technologies and provides the full portfolio of pharmaceutical documentation of GMP production processes, as well as production of units which are required for clinical approval. HALIX, as an end-to-end service provider, will serve its customers the full range from the first development steps to start of commercial production after successful registration of products.
Value Enhancement Strategy
- "HALIX" brand development
- Expansion: building a new, highly efficient pharmaceutical facility
- Establishment as an end-to-end service provider
- Increasing USP: excellent service quality
Contract Development and Manufacturing Organization (CDMO)
Acquisition of share
Corporate Venture and Spin-off of the HAL Allergy (spin-off in December 2012)
Chief Executive Officer
New cGMP facility
Since the ground breaking in July 2018, construction activities have been performed within 18 month time.
GMP Manufacturing of Proteins and Viruses
As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board...
NovalGen, a biopharmaceutical company developing breakthrough cancer therapies and HALIX, a contract development and manufacturing organisation, today...
HALIX B.V. signed an agreement with AstraZeneca AB for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based...
HALIX enters collaboration with the University of Oxford for GMP manufacturing of a COVID-19 vaccine
HALIX B.V. has joined a consortium of partners under the guidance of the University of Oxford, to provide GMP manufacturing services supporting the...
With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board consists of...
With an official inauguration ceremony, HALIX celebrated the opening of its 6,700 m2 brand-new cGMP facility at the Leiden Bioscience Park. On behalf...
HALIX meets aggressive timelines for new manufacturing facility. Following one year of construction, HALIX has completed its new state-of-the-art cGMP...
Kick-off for the construction activities for a 6.700 m² brand-new GMP facility at the Leiden Bio Science Park
HALIX has reached an important milestone in realising a brand-new 6.700 m² GMP facility with development and production clean rooms. By signing an...